Wegovy Tablet Approved
UK Approves Wegovy Weight Loss Tablet: Eligibility, Dosage, and Non-NHS Access Details
The UK's medicines regulator has approved a tablet version of the popular weight loss drug Wegovy, giving millions of Britons a needle-free option for tackling obesity. The Medicines and Healthcare products Regulatory Agency (MHRA) granted the green light on June 11, 2026, for oral semaglutide — the same active ingredient found in the Wegovy injection Daily Post.
Around 12 million UK adults meet the eligibility criteria, according to Lancs Live. But there is a major catch: the pill is not available on the NHS, meaning patients must pay privately — with costs expected to run between £150 and £250 per month.
Who Qualifies and How to Get the Pill
To be eligible, adults must have a Body Mass Index (BMI) of 30 or above. Those with a BMI between 27 and 30 can also qualify, but only if they have at least one weight-related health condition — such as high blood pressure or Type 2 diabetes Cambridge News.
Because the NHS does not currently cover the tablet, patients must go through a private doctor or online pharmacy. Major chains like Boots and Superdrug are updating their online doctor services to offer it. The MHRA says patients must carefully follow its Patient Information Leaflet to make sure the drug works safely Belfast Live.
Dose Starts Low and Climbs Slowly Over Months
The tablet follows a strict escalation schedule. Patients begin at 1.5 mg once daily. The dose then steps up to 4 mg, then 9 mg, and finally 25 mg. Each step requires at least one month at the lower dose before moving up Examiner Live.
The slow climb is deliberate. It helps the body adjust and reduces the risk of side effects. Clinical trials showed patients lost between 15% and 17% of their body weight over 68 weeks when combining the pill with lifestyle changes, according to Get Surrey.
Side Effects Are Common and Mostly Gut-Related
The most common side effects are gastrointestinal — meaning they affect the stomach and bowel. Nausea, diarrhoea, constipation, and vomiting are all listed as frequent complaints Daily Post. In clinical trials, up to 40% of participants reported these issues.
Experts warn the pill also demands strict daily compliance. It must be taken on an empty stomach with a specific amount of water. Professor Sir Stephen O'Rahilly of the University of Cambridge cautioned that "the biology of the gut is more volatile than the skin; if you don't follow the instructions, it simply won't work."
NHS Absence Risks Leaving Poorer Patients Behind
NICE — the body that decides what the NHS pays for — has deferred a recommendation on the tablet. It says it needs a separate cost analysis before making a call. Until then, NHS patients stay on long waiting lists for the injectable version Belfast Live.
Obesity UK and other patient groups have expressed mixed feelings. They welcome the new option but warn it risks becoming a "medicine for the wealthy." Those from lower-income backgrounds — who are disproportionately affected by obesity — are the least likely to afford the £150–£250 monthly private cost, according to Lancs Live.
Sentiment
NeutralPublishers
6
Articles
5
Reach
6
